前列环素用于COVID-19合并严重内皮病变的插管患者:多中心随机临床试验
本研究为多中心随机临床试验,纳入需机械通气且血浆血栓调节蛋白>4 ng/ml的成人COVID-19患者,随机接受72小时前列环素1 ng/kg/min输注或安慰剂。共80例随机(前列环素组41例,安慰剂组39例)。主要终点28天内无机械通气存活天数中位数前列环素组16.0天(SD 12)vs 安慰剂组5.0天(SD 10),中位数差值10.96天(95%CI -5至21;P=0.07)。28天死亡率前列环素组21.9% vs 安慰剂组43.6%(风险比0.50;95%CI 0.24至0.96;P=0.06);7天内严重不良事件发生率2.4% vs 12.8%(风险比0.19;95%CI 0.001至1.11;P=0.10)。结论认为前列环素未显著减少28天内无机械通气存活天数,但所有分析的点估计均倾向前列环素组,包括28天死亡率,需更大规模试验进一步研究。
要点
- 纳入标准:成人COVID-19、需机械通气、血浆血栓调节蛋白>4 ng/ml的严重内皮病变患者。
- 干预:随机接受72小时静脉输注前列环素1 ng/kg/min或安慰剂。
- 主要终点28天内无机械通气存活天数中位数:前列环素组16.0天(SD 12)vs 安慰剂组5.0天(SD 10),中位数差值10.96天(95%CI -5至21;P=0.07),未达统计学显著。
- 28天死亡率:前列环素组21.9% vs 安慰剂组43.6%(风险比0.50;95%CI 0.24至0.96;P=0.06),点估计倾向前列环素组但未达统计学显著。
- 7天内严重不良事件发生率:前列环素组2.4% vs 安慰剂组12.8%(风险比0.19;95%CI 0.001至1.11;P=0.10),未达统计学显著。
适用人群与场景
- 成人COVID-19患者,需机械通气,且血浆血栓调节蛋白>4 ng/ml(严重内皮病变)。
诊断标准与关键阈值
- 血浆血栓调节蛋白>4 ng/ml作为严重内皮病变的纳入标准。
处置流程与药物剂量
- 随机接受72小时静脉输注前列环素1 ng/kg/min或安慰剂。
研究设计与关键结果
- 多中心随机临床试验,80例随机(前列环素组41例,安慰剂组39例)。
- 主要终点28天内无机械通气存活天数中位数:前列环素组16.0天(SD 12)vs 安慰剂组5.0天(SD 10),中位数差值10.96天(95%CI -5至21;P=0.07)。
- 28天死亡率:前列环素组21.9% vs 安慰剂组43.6%(风险比0.50;95%CI 0.24至0.96;P=0.06)。
- 7天内严重不良事件发生率:前列环素组2.4% vs 安慰剂组12.8%(风险比0.19;95%CI 0.001至1.11;P=0.10)。
证据类型、等级与局限
- 证据类型:多中心随机临床试验。
- 局限:原文未报告局限性;作者在结论中提出需在更大规模试验中进一步研究(warranting further investigation in larger trials)。
对床旁实践的改变
- 作者认为,尽管主要终点未达统计学显著,但所有分析的点估计均倾向前列环素组,包括28天死亡率,需在更大规模试验中进一步研究。
指南或共识出处
- 临床试验注册号:www.clinicaltrials.gov(NCT04420741);EudraCT标识符:2020-001296-33。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rationale: The mortality in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who require mechanical ventilation remains high, and endotheliopathy has been implicated. Objectives: To determine the effect of prostacyclin infusion in mechanically ventilated patients infected with SARS-CoV-2 with severe endotheliopathy. Methods: We conducted a multicenter, randomized clinical trial in adults infected with coronavirus disease (COVID-19) who required mechanical ventilation and had a plasma level of thrombomodulin >4 ng/ml; patients were randomized to 72-hour infusion of prostacyclin 1 ng/kg/min or placebo. Measurements and Main Results: The main outcome was the number of days alive and without mechanical ventilation within 28 days. Key secondary outcomes were 28-day mortality and serious adverse events within 7 days. Eighty patients were randomized (41 prostacyclin and 39 placebo). The median number of days alive without mechanical ventilation at 28 days was 16.0 days (SD, 12) versus 5.0 days (SD, 10) (difference of the medians, 10.96 days; 95% confidence interval [CI], -5 to 21; P = 0.07) in the prostacyclin and the placebo groups, respectively. The 28-day mortality was 21.9% versus 43.6% in the prostacyclin and the placebo groups, respectively (risk ratio, 0.50; 95% CI, 0.24 to 0.96; P = 0.06). The incidence of serious adverse events within 7 days was 2.4% versus 12.8% (risk ratio, 0.19; 95% CI, 0.001 to 1.11; P = 0.10) in the prostacyclin and the placebo groups, respectively. Conclusions: Prostacyclin was not associated with a significant reduction in the number of days alive and without mechanical ventilation within 28 days. The point estimates, however, favored the prostacyclin group in all analyses, including 28-day mortality, warranting further investigation in larger trials. Clinical trial registered with www.clinicaltrials.gov (NCT04420741); EudraCT Identifier: 2020-001296-33.
参考来源
- Johansson PI, Søe-Jensen P, Bestle MH, et al. Prostacyclin in Intubated Patients with COVID-19 and Severe Endotheliopathy: A Multicenter, Randomized Clinical Trial. Am J Respir Crit Care Med. 2022. PMID: 34813414. doi:10.1164/rccm.202108-1855OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。